Pharmaceuticals - Community Register


Community register of orphan medicinal products


Product information


EU orphan designation number: EU/3/12/1022   
Active ingredient: Metreleptin
Indication: Treatment of Familial Partial Lipodystrophy
Sponsor: AstraZeneca AB
SE-151 85 Södertälje, Sverige

   Public summary of scientific opinion    


European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
19/07/2012 Centralised Orphan - Designation EMA/OD/033/12 (2012)5144 of 17/07/2012
14/02/2014 Centralised Orphan - Transfer of orphan designation EMA/OD/033/12/T/01 (2014)1032 of 12/02/2014
10/04/2014 Centralised Orphan - Transfer of orphan designation EMA/OD/033/12/T/02 (2014)2519 of 08/04/2014
17/06/2014 Centralised Orphan - Change of address